Featured Research

from universities, journals, and other organizations

Two-pronged approach successfully targets DNA synthesis in leukemic cells

Date:
February 24, 2014
Source:
The Rockefeller University Press
Summary:
A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice while sparing damage to normal blood cells, researchers have shown. Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis. These drugs are effective but have serious side effects on normal dividing tissues. Results of the new research indicate that there may be other ways to address leukemia while sparing the patient these side effects.

A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice, according to a study in The Journal of Experimental Medicine.

Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis. These drugs are effective but have serious side effects on normal dividing tissues.

In order to replicate, cells must make copies of their DNA, which is made up of building blocks called deoxyribonucleotide triphosphates (dNTPs). Cells can either make dNTPs from scratch (the "de novo" pathway) or by picking up the breakdown products of cells death (the "salvage" pathway). Caius Radu and colleagues at the University of California, Los Angeles now show that blocking the de novo pathway using thymidine causes leukemia cells to switch to the salvage pathway. This may explain why thymidine showed limited effectiveness as a single agent in clinical trials. Blocking both the de novo and salvage pathways was lethal for leukemic cells. The authors also found that a novel small molecule inhibitor of the salvage pathway enzyme deoxycytidine kinase blocked leukemia growth in mice in combination with thymidine (to inhibit the de novo pathway). Importantly, there was no significant toxicity to normal blood cell development. Why leukemic cells and normal blood cell precursors respond so differently to this treatment requires further investigation.

According to Radu, "this new dual targeting approach shows that we can overcome the redundancy in DNA synthesis in ALL cells and identifies a potential target for metabolic intervention in ALL, and possibly in other hematological cancers."

This interdisciplinary study not only advances our understanding of DNA synthesis in leukemic cells but also identifies targeted metabolic intervention as a new therapeutic approach in ALL. Clinical trials will be required to establish whether these promising findings will translate into a new therapeutic approach for ALL.


Story Source:

The above story is based on materials provided by The Rockefeller University Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. D. A. Nathanson, A. L. Armijo, M. Tom, Z. Li, E. Dimitrova, W. R. Austin, J. Nomme, D. O. Campbell, L. Ta, T. M. Le, J. T. Lee, R. Darvish, A. Gordin, L. Wei, H.-I. Liao, M. Wilks, C. Martin, S. Sadeghi, J. M. Murphy, N. Boulos, M. E. Phelps, K. F. Faull, H. R. Herschman, M. E. Jung, J. Czernin, A. Lavie, C. G. Radu. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. Journal of Experimental Medicine, 2014; DOI: 10.1084/jem.20131738

Cite This Page:

The Rockefeller University Press. "Two-pronged approach successfully targets DNA synthesis in leukemic cells." ScienceDaily. ScienceDaily, 24 February 2014. <www.sciencedaily.com/releases/2014/02/140224123636.htm>.
The Rockefeller University Press. (2014, February 24). Two-pronged approach successfully targets DNA synthesis in leukemic cells. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2014/02/140224123636.htm
The Rockefeller University Press. "Two-pronged approach successfully targets DNA synthesis in leukemic cells." ScienceDaily. www.sciencedaily.com/releases/2014/02/140224123636.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins